TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a surface receptor expressed primarily on microglia in the central nervous system. It serves as a critical regulator of microglial function, influencing phagocytosis, cellular survival, inflammatory responses, and metabolic adaptation. Rare coding variants in TREM2 confer significant risk for Alzheimer's disease (AD) and other neurodegenerative conditions, establishing microglial biology as a central pillar of neurodegeneration research. The discovery of TREM2's role in neurodegeneration represents a paradigm shift, moving beyond the neuron-centric view of disease to encompass the critical contributions of brain immune cells. [@trem2017a]
TREM2 is a type I transmembrane glycoprotein with the following structural features: [@trem2020a]
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a surface receptor expressed primarily on microglia in the central nervous system. It serves as a critical regulator of microglial function, influencing phagocytosis, cellular survival, inflammatory responses, and metabolic adaptation. Rare coding variants in TREM2 confer significant risk for Alzheimer's disease (AD) and other neurodegenerative conditions, establishing microglial biology as a central pillar of neurodegeneration research. The discovery of TREM2's role in neurodegeneration represents a paradigm shift, moving beyond the neuron-centric view of disease to encompass the critical contributions of brain immune cells. [@trem2017a]
TREM2 is a type I transmembrane glycoprotein with the following structural features: [@trem2020a]
TREM2 recognizes multiple ligands with varying affinities, each activating distinct downstream signaling programs: [@nasuhakola2015]
TREM2 functions as a lipid sensor via its extracellular Ig-like V-type domain:
TREM2 initiates an intracellular cascade through TYROBP (DAP12): [@trem2020b]
TREM2 bidirectionally regulates inflammation:
Pro-inflammatory (via NF-κB): IL-1β, TNF-α, COX-2, iNOS Anti-inflammatory (resolution): IL-10, TGF-β
DAM (Disease-Associated Microglia) program requires TREM2 signaling.
See: [Microglia-Neuroinflammation](/mechanisms/microglia-neuroinflammation)
Rare coding variants in TREM2 substantially increase AD risk: [@microglial2021]
| Variant | Effect | AD Risk (OR) | [@trem2021]
|---------|--------|---------------| [@trem2020c]
| R47H | Loss of function | ~3-4x increased | [@trem2021a]
| R62H | Partial loss | ~2x increased | [@trem2022]
| H157Y | Partial loss | ~2-3x increased |
| T66M | Complete loss | ~4x increased |
| Y38C | Complete loss | ~5x increased |
TREM2 variants have been implicated in:
The AD-risk variants function as partial loss-of-function mutations:
TREM2 plays a complex role in amyloid-beta clearance:
TREM2 influences tau propagation and toxicity:
TREM2 critically regulates microglial inflammatory responses:
TREM2 affects microglial metabolism:
Pharmacological activation of TREM2 represents a promising approach to restore microglial function in AD:
| Drug | Company | Phase | Mechanism | ClinicalTrials.gov |
|-----|---------|-------|----------|-------------------|
| AL002 | Alector/AbbVie | Phase II/III | Agonistic mAb | NCT04985669, NCT05462102 |
| AL003 | Alector | Preclinical | Agonistic mAb | -- |
| pyrotinib | NIMH (China) | Phase I | Agonistic mAb | -- |
| Approach | Mechanism | Stage | Key References |
|----------|-----------|-------|-----------|
| Agonistic antibodies | Activate receptor signaling | Phase II/III | Xiang 2024, NCT04985669 |
| sTREM2 mimetics | Soluble receptor fragments | Preclinical | -- |
| Gene therapy | Increase TREM2 expression | Preclinical | -- |
| Tyrobp enhancement | Enhance downstream signaling | Research | -- |
| MS4A modulation | Increase TREM2 surface | Research | Deming 2021 |
TREM2 intersects with multiple Alzheimer's disease mechanisms:
The signaling cascade initiated by TREM2 activation involves multiple downstream pathways that coordinately regulate microglial function. Understanding this cascade provides insight into the mechanisms by which TREM2 variants contribute to neurodegeneration and identifies potential therapeutic targets.
Upon ligand binding, TREM2 recruits the adaptor protein TYROBP (also known as DAP12) through interaction between their transmembrane domains. TYROBP contains an immunoreceptor tyrosine-based activation motif (ITAM) that becomes phosphorylated by Src family kinases following TREM2 clustering. This phosphorylation creates docking sites for the Syk kinase, which is activated upon recruitment.
Activated Syk initiates multiple downstream signaling cascades. The phosphoinositide 3-kinase (PI3K) pathway is activated, leading to the production of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) and activation of Akt. This pathway promotes cell survival and metabolic adaptation. The extracellular signal-regulated kinase (ERK) pathway is also activated, driving gene expression changes that support microglial activation.
The NF-κB pathway represents another critical downstream target. NF-κB activation leads to the transcription of inflammatory mediators and survival genes. The balance between productive and pathological NF-κB signaling is influenced by TREM2, with implications for the inflammatory environment in neurodegenerative diseases.
The relationship between TREM2 and lipid metabolism represents a major research focus, given the receptor's ability to bind lipid ligands and the established links between lipid metabolism and neurodegeneration.
Microglial lipid metabolism undergoes dramatic changes in association with neurodegenerative disease. The uptake of apoptotic cells and cellular debris provides a significant source of lipids that must be metabolized. TREM2 signaling supports the metabolic pathways required for this lipid processing, including cholesterol efflux and fatty acid oxidation.
Apolipoprotein E (ApoE), particularly the AD-risk ApoE4 isoform, represents a key TREM2 ligand. The interaction between TREM2 and ApoE-containing lipoproteins activates microglial phagocytosis and metabolic adaptation. The ApoE4 isoform shows enhanced binding to TREM2 compared to protective variants, potentially reflecting a compensatory mechanism that fails in the context of other AD risk factors.
The lipid-binding capacity of TREM2 extends to multiple lipid species, including phosphatidylserine, phosphatidylinositol, and various phospholipids. This broad lipid recognition enables TREM2 to sense diverse cellular stress conditions through the lipid signatures they produce.
The concept of microglial activation states has evolved significantly, with TREM2 playing a central role in defining the functional phenotype of disease-associated microglia (DAM).
DAM represent a specialized microglial population that emerges in the context of neurodegeneration. These cells are characterized by upregulated expression of TREM2 and other disease-associated genes, including APOE, ITGAX (CD11c), and genes involved in lipid metabolism. TREM2 is required for the full acquisition of the DAM phenotype, suggesting that TREM2 signaling drives this adaptive response.
The DAM phenotype is associated with both beneficial and potentially harmful functions. On the beneficial side, DAM demonstrate enhanced phagocytic capacity, supporting the clearance of pathological protein aggregates and cellular debris. On the potentially harmful side, DAM produce pro-inflammatory cytokines and may contribute to chronic neuroinflammation.
The TREM2-dependent DAM program appears to represent an attempt by the brain to cope with pathological challenges. When TREM2 function is impaired, as in individuals with risk variants, this adaptive response is compromised, potentially leading to reduced clearance of pathological features and accelerated disease progression.
Beyond its roles in immunity and phagocytosis, TREM2 influences synaptic function and plasticity through effects on microglial-neuronal interactions.
Microglia participate in synaptic pruning during development and in adult synaptic remodeling. This process involves the recognition and elimination of excess or inappropriate synapses, a critical step in neural circuit formation and refinement. TREM2 signaling supports microglial synaptic pruning, with implications for circuit development and plasticity.
In the adult brain, TREM2 continues to influence synaptic homeostasis. Microglial processes actively survey synapses and respond to synaptic activity, with TREM2 modulating this surveillance function. Alterations in TREM2 signaling may therefore affect activity-dependent synaptic modifications underlying learning and memory.
The complement system, particularly C1q and C3, mediates synaptic elimination by microglia. TREM2 interacts with complement signaling, potentially modulating the threshold for synaptic elimination. This interaction may be relevant to the synaptic loss observed in Alzheimer's disease.
While much attention has focused on amyloid pathology, tau pathology represents a critical driver of cognitive decline in Alzheimer's disease. TREM2 influences tau pathogenesis through multiple mechanisms.
Microglial responses to tau pathology are TREM2-dependent. In models of tauopathy, TREM2 deficiency reduces the microglial response to tau deposits, altering the inflammatory environment and potentially affecting tau clearance. This suggests that TREM2 modulates the brain's response to tau pathology.
The spread of tau pathology through connected brain regions represents a key feature of AD progression. Microglial cells may participate in this spread by taking up and releasing tau seeds. TREM2 signaling affects this process, with implications for the progression of tau pathology.
Therapeutic approaches targeting TREM2 may therefore affect tau pathogenesis both directly and indirectly through effects on microglial function.
The TREM2 variants that increase Alzheimer's disease risk show varying degrees of functional impairment, providing insight into the relative importance of different TREM2 functions.
The R47H variant, associated with approximately 3-4 fold increased AD risk, shows substantial impairment in ligand binding and signaling. Studies have demonstrated reduced binding to amyloid-beta aggregates, apolipoproteins, and lipid ligands. This broad impairment suggests that ligand binding capacity is critical for TREM2 function in the brain.
The R62H variant shows intermediate impairment, with partial reduction in ligand binding and signaling. The reduced penetrance of this variant compared to R47H is consistent with its less severe functional impairment.
The complete loss-of-function variants, including T66M and Y38C, are associated with even higher relative risk but are much rarer in the population. These variants causeFrames: complete ablation of TREM2 function and cause Nasu-Hakola disease when present in homozygous form.
Multiple approaches to therapeutically modulate TREM2 are in development, ranging from direct receptor activation to downstream pathway targeting.
TREM2-activating antibodies represent the most direct approach. These antibodies bind the TREM2 extracellular domain, either activating the receptor directly or enhancing responses to endogenous ligands. Several such antibodies have entered clinical development for Alzheimer's disease.
Small molecule agonists offer the potential for oral delivery and broader distribution. While no small molecule TREM2 agonists have reached clinical development, screening efforts are underway to identify compounds that can enhance TREM2 signaling.
Soluble TREM2 (sTREM2), the shedded ectodomain of the receptor, may have biological activity that can be exploited therapeutically. sTREM2 can function as a decoy receptor or may have signaling properties of its own.
Gene therapy approaches seek to increase TREM2 expression in the brain. Viral vector-mediated delivery could provide long-term restoration of TREM2 function in affected individuals.
The development of biomarkers for TREM2-targeted therapies is essential for patient selection and monitoring of treatment response.
Soluble TREM2 in cerebrospinal fluid represents the most direct biomarker of TREM2 biology. sTREM2 levels reflect shedding of the receptor and may indicate ongoing microglial activation. Changes in sTREM2 levels following treatment could indicate biological activity of TREM2-targeted therapeutics.
Imaging markers of microglial activation, including TSPO PET, provide measures of the inflammatory environment in the brain. These markers may be useful for assessing the downstream effects of TREM2 modulation.
Genetic testing for TREM2 variants enables identification of individuals who may be most likely to benefit from TREM2-targeted therapies. However, given the rarity of TREM2 variants, this approach limits the eligible patient population.
While most extensively studied in Alzheimer's disease, TREM2 has implications for other neurodegenerative conditions.
In Parkinson's disease, TREM2 expression is altered, and some genetic associations have been reported. The role of TREM2 in Parkinson's may relate to its function in microglial phagocytosis and inflammatory responses.
Amyotrophic lateral sclerosis (ALS) involves both motor neuron degeneration and microglial activation. Rare TREM2 variants have been identified in some ALS patients, suggesting a potential role in disease pathogenesis.
Frontotemporal dementia involves frontotemporal lobe degeneration with prominent microglial involvement. TREM2 may contribute to the inflammatory component of this disease category.
Multiple sclerosis presents an interesting case, as TREM2 risk variants show an inverse relationship with disease risk compared to Alzheimer's. This suggests that TREM2 may have context-dependent effects that vary with disease-specific pathological features.
Key questions remaining in TREM2 biology and therapy include:
Trem2 knockout mice represent the fundamental loss-of-function model. These mice develop normally, indicating that TREM2 is not essential for development. However, detailed characterization has revealed subtle phenotypes affecting microglial function and inflammatory responses. In the context of amyloid pathology, Trem2 deficiency reduces microglial clustering around plaques and alters plaque morphology.
Humanized knock-in models carrying the R47H variant have been developed to study the AD risk variant specifically. These mice show partial loss-of-function phenotypes, with reduced microglial activation in response to pathology. The model provides valuable insight into the mechanisms of the human risk variant.
Overexpression models allow examination of the effects of increased TREM2 signaling. These models demonstrate enhanced microglial responses and altered pathology in some contexts, providing evidence for the therapeutic potential of TREM2 activation.
Comprehensive phenotypic analysis of TREM2-modulated mice has revealed multiple alterations:
Motor and behavioral phenotypes: Some TREM2 models show subtle motor deficits, though these are highly dependent on genetic background and specific manipulation. Open field testing and rotarod assessment have been used to characterize these phenotypes.
Cognitive function: Learning and memory deficits have been reported in several models, particularly in the context of amyloid pathology. These deficits are consistent with the role of TREM2 in synaptic function.
Neuropathology: Detailed neuropathological analysis reveals altered plaque burden and morphology, changes in microglial distribution and morphology, and effects on synaptic markers. The nature of these changes varies with the specific model and disease context.
Biochemical alterations: Changes in protein expression, lipid metabolism, and inflammatory mediators have been characterized, providing insight into the pathways affected by TREM2 modulation.
Cell culture systems complement in vivo studies by enabling detailed mechanistic investigation:
Primary microglia: Cultured microglia from TREM2-modulated mice enable detailed study of receptor function, signaling, and cellular responses. These cells can be stimulated with various ligands to characterize TREM2-dependent responses.
Cell lines: Immortalized microglial cell lines provide a more tractable system for mechanistic studies. Several such lines have been used to characterize TREM2 signaling cascades.
iPSC-derived microglia: Human induced pluripotent stem cell (iPSC)-derived microglia represent a powerful system for studying human TREM2 variants. These cells can be generated from individuals with different TREM2 genotypes, enabling comparison of variant-specific effects.
The blood-brain barrier (BBB) represents a critical interface between the peripheral circulation and the central nervous system. TREM2 influences BBB function through multiple mechanisms with implications for neurodegeneration and therapeutic delivery.
TREM2 is expressed on brain endothelial cells, where it may participate in barrier function. The receptor's ligands include components of the vascular wall, and signaling may influence endothelial cell activation and barrier integrity.
In neurodegenerative conditions, BBB disruption is commonly observed. TREM2 may contribute to this disruption through effects on endothelial cell function and inflammatory responses. Alternatively, BBB dysfunction may alter TREM2 ligand availability, affecting microglial activation.
The BBB controls entry of peripheral immune cells into the CNS. TREM2 signaling may influence this process by affecting the expression of adhesion molecules and chemokines that control immune cell trafficking.
In multiple sclerosis and related conditions, peripheral immune cell entry is a key pathological feature. TREM2 variants that increase MS risk may do so through effects on immune cell trafficking, contrasting with the protective effect in Alzheimer's disease.
Therapeutic targeting of TREM2 in the CNS requires consideration of BBB penetration. Antibody therapeutics, in particular, face challenges in achieving adequate CNS exposure.
Strategies to enhance CNS delivery include:
Systems biology approaches have been applied to understand TREM2 function in the context of broader cellular networks. These analyses reveal TREM2 as a hub in networks regulating microglial function, immune responses, and lipid metabolism.
Gene co-expression networks identify genes that show coordinated expression with TREM2 across different conditions. These networks reveal modules enriched for immune function, lipid metabolism, and lysosomal pathways, providing insight into TREM2's biological context.
Protein-protein interaction networks identify proteins that interact with TREM2 or its signaling partners. These networks highlight the signaling cascade from TREM2 through TYROBP to downstream pathways.
Single-cell RNA sequencing has enabled detailed characterization of microglial populations in health and disease. These studies reveal substantial heterogeneity in microglial states, with TREM2 expression marking specific subpopulations.
Disease-associated microglia (DAM) represent one such subpopulation, characterized by upregulated TREM2 and coordinated gene expression programs. Single-cell analysis has revealed intermediate states in the DAM progression, providing insight into the dynamics of microglial activation.
The trajectory from homeostatic microglia to DAM can be modeled using pseudotime analysis, revealing the sequence of gene expression changes that accompany microglial activation. TREM2 expression appears in the intermediate stages of this trajectory.
Integration of genomic, transcriptomic, proteomic, and metabolomic data provides a systems-level view of TREM2 function. These approaches reveal the downstream consequences of TREM2 variant carriage and the effects of TREM2 modulation.
Proteomic studies have identified changes in protein expression following TREM2 activation or deletion. These changes span multiple pathways, including cytoskeletal dynamics, metabolic enzymes, and signaling proteins.
Metabolomic studies reveal alterations in lipid metabolism that accompany TREM2 dysfunction. These changes may be both cause and consequence of altered microglial function.
Genetic studies continue to refine our understanding of TREM2's role in neurodegeneration:
Population genetics: Large-scale sequencing studies continue to identify rare TREM2 variants and refine the effect sizes of known variants. These studies provide estimates of variant prevalence and disease risk in diverse populations.
Genome-wide association studies: While TREM2 is not a common variant gene, GWAS approaches continue to identify variants in regulatory regions that may affect TREM2 expression or function.
Family studies: Analysis of families with multiple affected members can identify novel TREM2 variants and provide insight into variant pathogenicity.
Individuals with TREM2 risk variants have been characterized in clinical studies:
Cognitive function: Testing of carriers and non-carriers reveals differences in cognitive performance, particularly in domains affected by Alzheimer's disease.
Neuroimaging: MRI and PET studies show differences in brain structure and function in carriers. Amyloid PET and tau PET reveal altered pathology in carriers.
Biomarker studies: CSF and blood biomarkers show differences in inflammatory markers, synaptic markers, and Alzheimer's disease biomarkers in carriers.
TREM2-targeted therapeutics are in various stages of clinical development:
Phase I trials: Safety and tolerability of anti-TREM2 antibodies have been assessed in healthy volunteers and Alzheimer's disease patients.
Phase II trials: Efficacy signals are being assessed in studies of anti-TREM2 antibodies in Alzheimer's disease. These trials include biomarker assessments to demonstrate target engagement.
Biomarker development: Studies of TREM2 biology in clinical samples are ongoing to identify biomarkers for patient selection and treatment response monitoring.
TREM2 participates in pathways that are relevant to multiple neurodegenerative conditions:
Microglial activation: Central to the inflammatory component of many neurodegenerative diseases Lipid metabolism: Dysregulated in multiple conditions Phagocytosis: Impaired in several diseases Synaptic support: Relevant to conditions with synaptic loss
Despite these shared pathways, TREM2 effects vary across diseases:
Alzheimer's disease: Primary focus of TREM2 research, with strong genetic evidence for role in amyloid and tau pathogenesis
Parkinson's disease: Less strong genetic evidence, but potential role in microglial responses to alpha-synuclein pathology
ALS: Rare variants identified, suggesting potential role in microglial support of motor neurons
Multiple sclerosis: Paradoxical inverse relationship with disease risk, suggesting context-dependent effects
Understanding the disease-specific and shared mechanisms of TREM2 has implications for therapeutic development:
Target validation: The genetic evidence for TREM2 in Alzheimer's disease supports targeting in this indication Patient selection: TREM2 variant carriers may represent a population with enhanced likelihood of benefit Combination approaches: Targeting TREM2 may complement other therapeutic modalities Safety considerations: Understanding TREM2's role in different diseases informs safety assessment